| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | NaN | NaN | -3,990 | 1,013 |
| Stock-based compensation | NaN | NaN | 138 | 136 |
| Loss on sale of subsidiary | NaN | NaN | 0 | 0 |
| Restructuring charges (impairment of long-lived assets) | NaN | NaN | 0 | NaN |
| Deferred income taxes and other items | NaN | NaN | -1,069 | -114 |
| Accounts receivable, net | NaN | NaN | 3,398 | 1,086 |
| Inventories | NaN | NaN | 1,653 | 51 |
| Other assets | NaN | NaN | -381 | -132 |
| Accounts payable and pharmacy claims and discounts payable | NaN | NaN | 1,221 | 1,212 |
| Reconciliation of net income to net cash provided by operating activities | 94,201 | 389,128 | NaN | NaN |
| Health care costs payable and other insurance liabilities | NaN | NaN | 768 | -398 |
| Net income | 50,551 | 216,493 | NaN | NaN |
| Other liabilities | NaN | NaN | 1,110 | -118 |
| Adjustments required to reconcile net income to net cash provided by operating activities | 28,398 | 121,238 | NaN | NaN |
| Goodwill impairment | NaN | NaN | 5,725 | NaN |
| Depreciation and amortization | 10,775 | 37,570 | NaN | NaN |
| Gain on deconsolidation of subsidiary | NaN | NaN | 483 | NaN |
| Loss on assets held for sale | 526 | 1,969 | NaN | NaN |
| Interest paid | 1,091 | 2,991 | NaN | NaN |
| Depreciation and amortization | NaN | NaN | 1,134 | 1,171 |
| Income taxes refunded (paid) | -337 | 2,166 | NaN | NaN |
| Net cash provided by operating activities | 4,249 | 3,390 | 796 | 1,897 |
| Proceeds from sales and maturities of investments | 4,159 | 2,743 | 2,774 | 3,332 |
| Purchases of investments | 4,186 | 3,967 | 3,859 | 3,634 |
| Purchases of property and equipment | 849 | 784 | 698 | 607 |
| Acquisitions | 5 | 7 | 290 | 119 |
| Other | -7 | -17 | 14 | -4 |
| Net cash used in investing activities | -874 | -1,998 | -2,087 | -1,024 |
| Commercial paper borrowings (repayments), net | 0 | -1,247 | -1,793 | 1,780 |
| Proceeds from issuance of short-term loan | NaN | 0 | NaN | NaN |
| Repayment of short-term loan | NaN | 0 | NaN | NaN |
| Proceeds from issuance of long-term debt | NaN | 0 | 3,969 | 0 |
| Repayments of long-term debt | 1,518 | 20 | 2,847 | 19 |
| Repurchase of common stock | NaN | 0 | 0 | 0 |
| Dividends paid | 847 | 845 | 846 | 866 |
| Proceeds from exercise of stock options | 103 | 86 | 117 | 47 |
| Payments for taxes related to net share settlement of equity awards | 9 | 13 | 20 | 114 |
| Other | -47 | 7 | 38 | -22 |
| Net cash used in financing activities | -2,318 | -2,032 | -1,382 | 806 |
| Net increase in cash, cash equivalents and restricted cash | 1,057 | -640 | -2,673 | 1,679 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 8,712 | 9,352 | 12,025 | 10,346 |
| Cash, cash equivalents and restricted cash at the end of the period | 9,769 | 8,712 | 9,352 | 12,025 |
CVS HEALTH Corp (CVS)
CVS HEALTH Corp (CVS)